

# Chronic Pulmonary Aspergillosis and Ambisome Aerosol with Itraconazole

NCT03656081

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Poitiers University Hospital
<b>Enrollment</b>	224 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- All adult patients affected with Chronic Pulmonary Aspergillosis (CPA) "de novo" or in relapse (without any history of resistance to itraconazole) combining the following criteria are eligible:
- Patient with an Aspergillus bronchopulmonary infection, be it cavitary, fibrotic, necrotizing (SIA/Semi Invasive Aspergillosis) or nodular and documented by compatible thoracic CT-scan images ;
- Associated with one of the following criteria:
- positive detection of anti-Aspergillus IgG and/or precipitating anti-aspergillus antibodies, according to the positivity threshold of the laboratory performing the technique,
- positive direct examination of Aspergillus or positive culture, from bronchopulmonary samples (expectoration or endoscopic aspiration),

... and 6 more (see full listing online)

### Exclusion (24)

- \- Patient affected with single aspergilloma
- \- Patient presenting a contraindication to itraconazole (including all contraindicated co-administrated medications as listed in the itraconazole SmPc, including notably medications with potential to prolong theQT interval)
- \- Patient presenting a contraindication to voriconazole and posaconazole (including all contraindicated coadministrated medications as listed in the SmPc)
- \- Intolerance to beta2-agonists
- \- Notion of relapse with isolation of an Aspergillus resistant to itraconazole

... and 19 more (see full listing online)

## Locations (1 total)

---

CHU Poitiers, Poitiers, France